NewLink Genetics Corp. (NASDAQ:NLNK)’s share price shot up 2.6% during mid-day trading on Tuesday . The company traded as high as $10.36 and last traded at $10.30, with a volume of 73,447 shares. The stock had previously closed at $10.04.

A number of research firms have issued reports on NLNK. Zacks Investment Research downgraded NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Robert W. Baird restated a “buy” rating on shares of NewLink Genetics Corp. in a report on Monday, May 16th. Jefferies Group restated a “hold” rating and set a $10.00 price target on shares of NewLink Genetics Corp. in a report on Wednesday, May 11th. SunTrust Banks Inc. downgraded NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and reduced their price target for the company from $59.00 to $12.00 in a report on Tuesday, May 10th. Finally, Mizuho reduced their price target on NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $23.29.

The company’s 50 day moving average is $10.60 and its 200-day moving average is $14.09. The firm’s market cap is $294.90 million.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings results on Friday, July 29th. The company reported ($1.12) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.35. Equities analysts predict that NewLink Genetics Corp. will post ($3.06) EPS for the current fiscal year.

An institutional investor recently raised its position in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP raised its stake in shares of NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned approximately 0.17% of NewLink Genetics Corp. worth $1,765,000 at the end of the most recent quarter.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.